Current Issue

December 2025

Looking to the Past to Advance the Future

Hematology has transformed significantly since 2000 and is poised to see even more revolutionary breakthroughs by 2050.

Viewpoints

Editor’s Corner

The Final Note

Letter to the Editor

Proposals for the Next Classification Schema of Acute Leukemia and Myeloid Neoplasms 50 Years After the Original Classification

Education

You Make the Call

You Make the Call: How would you treat a patient with low FVII but no history of bleeding, desiring an epidural injection?

You Make the Call: Readers' Response

How would you treat a patient with low FVII but no history of bleeding, desiring an epidural injection?

Algorithms in Hematology

Should I Go to a Theme Park?

Spotlight

Feature Articles

Looking to the Past to Advance the Future

Drawing First Blood

Should Early-Stage MCL Be Treated Aggressively or Not?

Pulling Back the Curtain

Pulling Back the Curtain: Robert S. Negrin, MD

News

In a Different Vein: News from the Blood Journals

Isatuximab Shows High Response Rates in Relapsed, Refractory Light Chain Amyloidosis

Literature Scan

ATRA-ATO Combination Therapy Improves Efficacy for Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia Over Standard of Care

The Society Pages

Remembering Susan B. Shurin (1944 – 2025)

ASH Directions

Three New Leaders Elected to the ASH Executive Committee
Launch of ASH IGNITE Connects Hematology Entrepreneurs With Business Resources, Networking Opportunities

Data Stream

December 2025 Data Stream

Year in Review

2025 Year in Review

Online Only

Literature Scan

Study Uncovers Infection Burden Among Patients with Smoldering Myeloma
Phase II Study Confirms Pemigatinib Efficacy, Tolerability in Myeloid, Lymphoid Neoplasms With FGFR1 Rearrangements

The Search for Research

A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma (NCT06563596)
waveLINE-010: A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (NCT06717347)

Latest & Greatest

In Vivo CAR-T Therapy Receives Fast Track Designation
FDA Approves R/R AML Treatment
R/R MM Drug Receives FDA Approval
FDA to Accelerate Biosimilar Development
Recipients of the 2025 Nobel Prize in Physiology or Medicine Announced

The Society Pages

Versiti Names CCBD Program Director